Prophylactic proton pump inhibition after atrial fibrillation ablation: Is there any evidence?

Europace

Volumn 13, Issue 9, 2011, Pages 1219-1221

  Zellerhoff, Stephan ^a   Lenze, Frank ^a   Eckardt, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Atrial fibrillation; Atrio oesophageal fistula; Catheter ablation; Endoscopy

Indexed keywords

PROTON PUMP INHIBITOR;

CATHETER ABLATION; DRUG MECHANISM; ESOPHAGUS FISTULA; HEART ATRIUM FIBRILLATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; REVIEW;

ATRIAL FIBRILLATION; CATHETER ABLATION; ESOPHAGEAL FISTULA; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 80052257744     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur139     Document Type: Review

References (34)

1. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 12:1360-420.
2. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NAM et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:104-23.
3. Pappone C, Oral H, Santinelli V, Vicedomini G, Lang CC, Manguso F et al. Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation 2004;109:2724-6. (Pubitemid 38737918)
4. Zellerhoff S, Lenze F, Schulz R, Eckardt L. Fatal course of esophageal stenting of an atrioesophageal fistula after atrial fibrillation ablation. Heart Rhythm 2011;8: 624-6.
5. Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythmia Electrophysiol 2010;3:32-8.
6. Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009;53:1798-803.
7. Stö llberger C, Pulgram T, Finsterer J. Neurological consequences of atrioesophageal fistula after radiofrequency ablation in atrial fibrillation. Arch Neurol 2009;66:884-7.
8. Singh S, d'Avila A, Doshi S, Brugge W, Bedford R, Mela T et al. Esophageal injury and temperature monitoring during atrial fibrillation ablation. Circ Arrhythmia Electrophysiol 2008;1:162-8.
9. Schmidt M, Nö lker G, Marschang H, Gutleben K-J, Schibgilla V, Rittger H et al. Incidence of oesophageal wall injury post-pulmonary vein antrum isolation for treatment of patients with atrial fibrillation. Europace 2008;10:205-9. (Pubitemid 351767714)
10. Zellerhoff S, Ullerich H, Lenze F, Meister T, Wasmer K, Mö nnig G et al. Damage to the esophagus after atrial fibrillation ablation: Just the tip of the iceberg? High prevalence of mediastinal changes diagnosed by endosonography. Circ Arrhythmia Electrophysiol 2010;3:155-9.
11. Halm U, Gaspar T, Zachäus M, Sack S, Arya A, Piorkowski C et al. Thermal esophageal lesions after radiofrequency catheter ablation of left atrial arrhythmias. Am J Gastroenterol 2010;105:551-6.
12. Martinek M, Meyer C, Hassanein S, Aichinger J, Bencsik G, Schoefl R et al. Identification of a high-risk population for esophageal injury during radiofrequency catheter ablation of atrial fibrillation: procedural and anatomical considerations. Heart Rhythm 2010;7:1224-30.
13. Calkins H, Brugada J, Packer DL, Cappato R, Chen S-A, Crijns HJG et al. HRS/ EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 2007;9:335-79.
14. Martinek M, Hassanein S, Bencsik G, Aichinger J, Schoefl R, Bachl A et al. Acute development of gastroesophageal reflux after radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2009;6:1457-62.
15. Yokoyama K, Nakagawa H, Seres KA, Jung E, Merino J, Zou Y et al. Canine model of esophageal injury and atrial-esophageal fistula after applications of forward-firing high-intensity focused ultrasound and side-firing unfocused ultrasound in the left atrium and inside the pulmonary vein. Circ Arrhythm Electrophysiol 2009;2:41-9.
16. Shah D, Dumonceau J, Burri H, Sunthorn H, Schroft A, Gentil-Baron P et al. Acute pyloric spasmand gastric hypomotility: An extracardiac adverse effect of percutaneous radiofrequency ablation for atrial fibrillation. J AmColl Cardiol 2005;46:327-30. (Pubitemid 40966864)
17. Bunch TJ, Ellenbogen KA, Packer DL, Asirvatham SJ. Vagus nerve injury after posterior atrial radiofrequency ablation. Heart Rhythm 2008;5:1327-30.
18. Grubina R, Cha Y-M, Bell MR, Sinak LJ, Asirvatham SJ. Pneumopericardium following radiofrequency ablation for atrial fibrillation: Insights into the natural history of atrial esophageal fistula formation. J Cardiovasc Electrophysiol 2010;21:1046-49.
19. Vijayaraman P, Netrebko P, Geyfman V, Dandamudi G, Casey K, Ellenbogen KA. Esophageal fistula formation despite esophageal monitoring and low-power radiofrequency catheter ablation for atrial fibrillation. Circ Arrhythmia Electrophysiol 2009;2:e31-3.
20. GilcreaseGW, Stein JB. A delayed case of fatal atrioesophageal fistula following radiofrequency ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2010;21:708-11.
21. Tilz RR, Chun KRJ, Metzner A, Burchard A, Wissner E, Koektuerk B et al. Unexpected high incidence of esophageal injury following pulmonary vein isolation using robotic navigation. J Cardiovasc Electrophysiol 2010;21:853-8.
22. Nö lker G, Ritscher G, Gutleben K-J, Marschang H, Schmidt M, Rittger H et al. Esophageal acid levels after pulmonary vein isolation for atrial fibrillation. Pacing Clin Electrophysiol 2009;32(Suppl. 1):S228-30.
23. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:528-34.
24. Shi S, Klotz U. Proton pump inhibitors: An update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-51.
25. IMS Health reports U.S. prescription sales grew 5.1 percent in 2009, to $$300.3 billion. http://www.imshealth.com/portal/site/imshealth/ menuitem.a46c6d4df3db 4b3d88f611019418c22a/?vgnextoid= d690a27e9d5b7210VgnVCM100000ed152 ca2RCRD&vgnextfmt=default (1 February 2011, date last accessed).
26. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; CD003244.
27. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008; 359:1700-7.
28. Shaheen NJ, Stuart E, Schmitz SM, Mitchell KL, Fried MW, Zacks S et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial. Hepatology 2005;41:588-94. (Pubitemid 40289507)
29. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44.
30. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, HanssenMet al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: Results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry. Circulation 2011;123:474-82.
31. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56; quiz 57. (Pubitemid 47301504)
32. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301:2120-8.
33. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904.
34. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101.